The 32-Second Options Trading "Training Video" Retirees Can't Get Enough Of
Options expert Jeff Clark is on a mission to show every American at or near retirement how easy it is to trade options.
Watch his 32-second options trading "training vide
Seth Lederman, insider at Tonix Pharmaceuticals

Seth Lederman Insider Information

Seth Lederman is a physician, scientist and founder and executive officer of innovative biopharmaceuticals companies. Prior to founding Tonix, among the companies Dr. Lederman founded was Targent Pharmaceuticals, which developed late-stage oncology drugs, including pure-isomer levofolinic acid (levoleucovorin). Targent’s assets were sold to Spectrum Pharmaceuticals, which marketed levoleucovorin as Fusilev® for advanced colorectal cancer, where it gained significant market acceptance.  

Dr. Lederman served as an Associate Professor at Columbia University from 1996 until April 13, 2017. He joined the faculty of Columbia University's College of Physicians and Surgeons in 1985, became Assistant Professor of Medicine in 1988, and Associate Professor with tenure in 1996 and Director of the Laboratory of Molecular Immunology in 1997. From 1988 to 2002, Dr. Lederman directed basic science research at Columbia in molecular immunology, infectious diseases and the development of therapeutics for autoimmune diseases. Dr. Lederman is author of numerous scientific articles, and inventor of technologies recognized by a number of issued patents. His fundamental work on the CD40-Ligand (CD154) elucidated the molecular basis of T cell helper function and has led to the development of therapeutic candidates for autoimmune diseases and organ transplant rejection in collaboration with Biogen and UCB. The successful defense of his CD154 patents has led to important precedents in defining the relationship of therapeutics and molecular targets. In collaboration with Prof. David Baltimore (then at Rockefeller University and later MIT), Dr. Lederman identified and functionally characterized the CD40 signaling molecule, TRAF-3. His early work on HIV contributed to the understanding of how the V3 loop of HIV gp120 was involved in fusion with CD4 cell membranes, an early and essential event in viral entry and infection. In addition to his research, Dr. Lederman served as attending physician in the Edward Daniels Arthritis and Autoimmunity Clinic on the Medical Service at Columbia Presbyterian Hospital from 1988-1996.  

Dr. Lederman represented U.S. Biotechnology at a Beijing Summit in September 2015 with China’s President Xi Jinping. The Summit was organized by the U.S. Chamber of Commerce and involved a delegation of U.S. CEOs, former U.S. Cabinet officials and leading academic experts. 

Dr. Lederman earned an AB from Princeton in Chemistry cum laude in 1979 and an MD from Columbia University's College of Physicians and Surgeons in 1983. Dr. Lederman trained in internal medicine and rheumatology at Columbia's Presbyterian Hospital. He was an NIH Physician-Scientist 1985-1990 at Columbia.

What is Seth Lederman's net worth?

The estimated net worth of Seth Lederman is at least $33,929.00 as of June 29th, 2022. Dr. Lederman owns 24,235 shares of Tonix Pharmaceuticals stock worth more than $33,929 as of August 15th. This net worth estimate does not reflect any other investments that Dr. Lederman may own. Additionally, Dr. Lederman receives an annual salary of $1,180,000.00 as CEO at Tonix Pharmaceuticals. Learn More about Seth Lederman's net worth.

How old is Seth Lederman?

Dr. Lederman is currently 64 years old. There are 2 older executives and no younger executives at Tonix Pharmaceuticals. Learn More on Seth Lederman's age.

What is Seth Lederman's salary?

As the CEO of Tonix Pharmaceuticals Holding Corp., Dr. Lederman earned a total compensation package of $7,708,389.00 in 2021. Dr. Lederman earned a salary of $675,000.00, a bonus of $506,250.00, options awards of $6,527,139.00, and no other miscellaneous compensation. Learn More on Seth Lederman's salary.

How do I contact Seth Lederman?

The corporate mailing address for Dr. Lederman and other Tonix Pharmaceuticals executives is 509 MADISON AVENUE SUITE 1608, NEW YORK NY, 10022. Tonix Pharmaceuticals can also be reached via phone at (212) 980-9155 and via email at [email protected] Learn More on Seth Lederman's contact information.

Has Seth Lederman been buying or selling shares of Tonix Pharmaceuticals?

Seth Lederman has not been actively trading shares of Tonix Pharmaceuticals during the past quarter. Most recently, on Wednesday, June 29th, Seth Lederman bought 20,000 shares of Tonix Pharmaceuticals stock. The stock was acquired at an average cost of $1.71 per share, with a total value of $34,200.00. Following the completion of the transaction, the chief executive officer now directly owns 24,235 shares of the company's stock, valued at $41,441.85. Learn More on Seth Lederman's trading history.

Who are Tonix Pharmaceuticals' active insiders?

Tonix Pharmaceuticals' insider roster includes Daniel Goodman (Director), and Seth Lederman (CEO). Learn More on Tonix Pharmaceuticals' active insiders.

Are insiders buying or selling shares of Tonix Pharmaceuticals?

In the last year, Tonix Pharmaceuticals insiders bought shares 3 times. They purchased a total of 132,000 shares worth more than $65,520.00. The most recent insider tranaction occured on June, 29th when CEO Seth Lederman bought 20,000 shares worth more than $34,200.00. Insiders at Tonix Pharmaceuticals own 2.0 % of the company. Learn More about insider trades at Tonix Pharmaceuticals.

Information on this page was last updated on 6/29/2022.

Seth Lederman Insider Trading History at Tonix Pharmaceuticals

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
6/29/2022Buy20,000$1.71$34,200.0024,235View SEC Filing Icon  
3/25/2022Buy100,000$0.24$24,000.00View SEC Filing Icon  
9/28/2021Buy12,000$0.61$7,320.00View SEC Filing Icon  
3/24/2021Buy16,733$1.32$22,087.56177View SEC Filing Icon  
8/13/2020Buy60,000$0.91$54,600.00177View SEC Filing Icon  
12/3/2019Buy20,000$1.16$23,200.00177View SEC Filing Icon  
3/29/2019Buy5,000$2.49$12,450.001,767View SEC Filing Icon  
3/26/2019Buy25,000$2.38$59,500.001,767View SEC Filing Icon  
6/29/2018Buy500$4.64$2,320.0017,666View SEC Filing Icon  
6/27/2018Buy500$4.55$2,275.0016,666View SEC Filing Icon  
6/12/2018Buy3,000$4.37$13,110.00View SEC Filing Icon  
5/25/2018Buy4,000$3.17$12,680.0011,166View SEC Filing Icon  
12/26/2017Buy5,300$3.61$19,133.0011,166View SEC Filing Icon  
8/17/2017Buy20,000$3.00$60,000.0011,166View SEC Filing Icon  
6/30/2017Buy5,000$4.33$21,650.007,912View SEC Filing Icon  
6/26/2017Buy5,000$4.40$22,000.007,912View SEC Filing Icon  
6/20/2017Buy20,000$4.22$84,400.007,912View SEC Filing Icon  
6/22/2016Buy20,000$2.08$41,600.0080,815View SEC Filing Icon  
3/23/2016Buy8,000$2.44$19,520.0080,815View SEC Filing Icon  
9/25/2015Buy6,000$6.50$39,000.0071,074View SEC Filing Icon  
3/17/2015Buy2,000$7.02$14,040.00View SEC Filing Icon  
3/13/2015Buy2,000$7.24$14,480.00View SEC Filing Icon  
3/11/2015Buy2,000$6.95$13,900.00View SEC Filing Icon  
3/9/2015Buy2,000$6.48$12,960.00View SEC Filing Icon  
3/5/2015Buy2,000$6.27$12,540.00View SEC Filing Icon  
See Full Table

Seth Lederman Buying and Selling Activity at Tonix Pharmaceuticals

This chart shows Seth Lederman's buying and selling at Tonix Pharmaceuticals by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Tonix Pharmaceuticals Company Overview

Tonix Pharmaceuticals logo
Tonix Pharmaceuticals Holding Corp., a clinical-stage biopharmaceutical company, focuses on discovering, acquiring, developing, and licensing therapeutics and diagnostics to treat and prevent human disease and alleviate suffering. Its portfolio includes immunology, rare disease, infectious disease, and central nervous system (CNS) product candidates. The company's immunology portfolio includes biologics to address organ transplant rejection, autoimmunity, and cancer, including TNX-1500, a humanized monoclonal antibody targeting CD40-ligand being developed for the prevention of allograft and xenograft rejection and for the treatment of autoimmune diseases. Its rare disease portfolio comprises TNX-2900 for the treatment of Prader-Willi syndrome. The company's infectious disease pipeline includes TNX-801, a vaccine to prevent smallpox and monkeypox; TNX-1840 and TNX-1850 that are live virus vaccines based on its recombinant pox vaccine (RPV) platform for COVID-19; TNX-3500, a small molecule antiviral drug to treat acute COVID-19; and TNX-102 SL, a small molecule drug to treat Long COVID, a chronic post-acute COVID-19 condition. Its CNS portfolio includes small molecules and biologics to treat pain, neurologic, psychiatric, and addiction conditions, including TNX-102 SL, which is in mid-Phase 3 development for the management of fibromyalgia; TNX-1900 that is in development for the prevention of migraine headache; and TNX-1300, a biologic designed to treat cocaine intoxication. The company was founded in 2007 and is headquartered in Chatham, New Jersey.
Read More

Today's Range

Now: $1.59
Low: $1.39
High: $1.65

50 Day Range

MA: $1.67
Low: $1.19
High: $2.30

2 Week Range

Now: $1.59
Low: $1.19
High: $24.89

Volume

8,597,752 shs

Average Volume

5,058,444 shs

Market Capitalization

$68.47 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.54
The Safest Option in Trades!
If you’re new to trading, then you’ve probably heard the wrong thing about options—that they’re risky, unpredictable, or difficult.

And it couldn’t be more wrong! With the Hughes Optioneering Strategy, you’ll soon learn that the safest option for new accounts is options themselves!
Click here now!